Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786538 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HPGDUSP2VCPKMT2A | |
| SCHEMBL3786803 | 0.88 | PKM (0.46) | ALDH1A1HPGDUSP2KMT2AADAM17 | |
| SCHEMBL3786809 | 0.88 | PKM (0.46) | ALDH1A1HPGDUSP2KMT2AADAM17 | |
| SCHEMBL19975037 | 0.80 | SIGMAR1 (0.48) | ALDH1A1HPGDUSP2KMT2AHDAC3 | |
| SCHEMBL11217670 | 0.80 | CXCR4 (0.56) | ALDH1A1HPGDUSP2VCPKMT2A | |
| SCHEMBL11217673 | 0.80 | CXCR4 (0.56) | ALDH1A1HPGDUSP2VCPKMT2A | |
| SCHEMBL714386 | 0.80 | KMT2A (0.59) | ALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL714385 | 0.80 | KMT2A (0.59) | ALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL6522964 | 0.80 | KMT2A (0.59) | ALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL19974816 | 0.79 | HDAC3 (0.41) | ALDH1A1HPGDUSP2KMT2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116526-B1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-04-18 | — | — | EP | claimed |
| US-8268884-B2 | Derivatives of substituted tartaric acid and usage for preparing beta-secretase inhibitors | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2012-09-18 | — | — | US | claimed |
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-12-30 | — | — | US | claimed |
| EP-2116526-A1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2009-11-11 | — | — | EP | claimed |
| EP-2116526-B1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-04-18 | — | — | EP | disclosed |
| US-8268884-B2 | Derivatives of substituted tartaric acid and usage for preparing beta-secretase inhibitors | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2012-09-18 | — | — | US | disclosed |
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-12-30 | — | — | US | disclosed |
| EP-2116526-A1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | ALDH1A1 692/4885HPGD 1546/4885USP2 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.